Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.15

€4.15

3.100%
0.123
3.100%
€6.92
 
27.03.24 / Tradegate WKN: A2DTR7 / Symbol: MRSN / Name: Mersana Therapeutics / Stock / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Mersana Therapeutics Stock

Mersana Therapeutics dominated the market today, gaining €0.12 (3.100%).
With 6 Buy predictions and not the single Sell prediction the community is currently very high on Mersana Therapeutics.
With a target price of 6 € there is a positive potential of 44.51% for Mersana Therapeutics compared to the current price of 4.15 €.
So far the community has only identified positive things for Mersana Therapeutics stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Pros and Cons of Mersana Therapeutics in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-11

Mersana Therapeutics, operating under the US symbol MRSN, is a company that specializes in the pharmaceutical industry. Upon examining its financial statements, it is evident that there is a combination of strengths and weaknesses in the company's financial performance.

Increasing Revenue: Over the years, Mersana Therapeutics has seen an increase in its total revenue, with the numbers going up from $0.83 million in 2020 to $2.66 million in 2021, and $26.58 million in 2022. This suggests that the company has been successful in generating more income, which is a positive sign for future growth.

Substantial Cash and Cash Equivalents: Mersana Therapeutics has maintained a considerable amount of cash and short-term investments over the years. The company had $255.1 million at the end of 2020 and $280.7 million in 2022. This indicates that the company has a sufficient liquidity position to meet its short-term obligations, invest in potential growth, and carry out its operations smoothly.

Comments

Prediction Buy
Perf. (%) -16.96%
Target price 8.295
Change
Ends at 28.02.25

Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -16.96%
Target price 5.535
Change
Ends at 28.02.25

Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $6.00 price target on the stock.
Ratings data for MRSN provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 129.01%
Target price 4.606
Change
Ends at 04.12.24

Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $5.00 price target on the stock, up previously from $1.00.
Ratings data for MRSN provided by MarketBeat
Show more